Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ValiRx plc ( (GB:VAL) ) just unveiled an announcement.
ValiRx, together with TwinEdge Bioscience and its subsidiary Inaphaea Biolabs, will present peer-reviewed data at the AACR meeting in San Diego showcasing a framework that combines omics-based digital avatars with patient-derived cancer models to accelerate precision oncology. This marks the first peer-reviewed publication of ValiRx’s patient-derived cancer digitisation approach, reinforcing its push into data-driven oncology and offering greater visibility among major pharmaceutical companies.
Inaphaea has also contributed an editorial in Drug Discovery World on how patient-derived models can bridge the translational gap in oncology, while ValiRx and academic collaborators published findings in Epigenomics on enhancing Carboplatin efficacy in aggressive prostate cancer. CEO Dr Mark Eccleston has been actively presenting the company’s oncolytic peptide data and serving on expert panels at multiple industry conferences, underscoring growing recognition of ValiRx’s NAMs platforms and immuno-oncology programmes and supporting its strategy to attract partners and collaborators.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.38 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
Spark’s Take on VAL Stock
According to Spark, TipRanks’ AI Analyst, VAL is a Neutral.
ValiRx plc’s overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and reliance on external financing. The technical analysis suggests a bearish trend, with some potential for upward movement. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on VAL stock, click here.
More about ValiRx plc
ValiRx plc is a London-listed life science company focused on early-stage cancer therapeutics and women’s health. It provides scientific, financial, and commercial frameworks to translate novel drug candidates from pre-clinical research into clinic-ready and investor-ready assets, often outlicensing or partnering its lead programmes via subsidiary companies for further development and commercialisation.
Average Trading Volume: 6,942,194
Technical Sentiment Signal: Strong Sell
Current Market Cap: £2.19M
Learn more about VAL stock on TipRanks’ Stock Analysis page.